Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.65 – $1.75
Volume16,429
Market cap$1M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$931.22K
Price / earnings
—
Price / book
0.15×
Price / sales
—
EV / sales
—
EV / EBITDA
0.36×
Profitability
Earnings per share
-$20.66
Return on assets
-169.57%
Return on equity
-181.51%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
10.47×
Quick ratio
10.47×
Cash ratio
10.11×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$11.76M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ARTL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$989K
$1.63M
$1.92M
$1.89M
$1.81M
$1.28M
$995K
$1.34M
Research and development
$803K
$876K
$773K
$893K
$1.28M
$1.87M
$1.38M
$2.48M
Total operating expenses
$1.79M
$2.51M
$2.69M
$2.79M
$3.09M
$3.15M
$2.38M
$3.81M
Operating income
-$1.79M
-$2.51M
-$2.69M
-$2.79M
-$3.09M
-$3.15M
-$2.38M
-$3.81M
Interest expense
$0
-$6K
-$124K
-$94K
-$111K
-$72K
$0
$0
Income before taxes
-$1.77M
-$2.43M
-$2.96M
-$4.17M
-$3.12M
-$3.22M
-$2.37M
-$3.78M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.77M
-$2.43M
-$2.96M
-$4.17M
-$3.12M
-$3.22M
-$2.37M
-$3.78M
Net income attributable to common shareholders
-$1.77M
-$2.43M
-$2.96M
-$4.17M
-$3.12M
-$3.22M
-$2.37M
-$3.78M
EBITDA
-$1.79M
-$2.51M
-$2.69M
-$2.79M
-$3.09M
-$3.15M
-$2.38M
-$3.81M
Basic earnings per share
-$3.19
-$8.01
-$36.00
-$51.39
-$88.80
-$151.74
-$112.95
-$189.19
Diluted earnings per share
-$3.19
-$8.01
-$36.00
-$51.39
-$88.80
-$151.74
-$112.95
-$189.19
Recent news
Company coverage with links to the original publishers.
Artelo Biosciences reminds shareholders to submit proxies in advance of its Annual Meeting scheduled for July 17, 2026. The company emphasizes that proxy submissions help establish quorum regardless of voting direction, and notes that failure to achieve quorum could result in meeting adjournment and additional expenses.
Artelo Biosciences completed a private placement raising $11.0 million through the sale of 3.2 million shares and warrants at $3.45 per share. The company plans to use proceeds for working capital, general corporate purposes, and bridge debt repayment. Warrants could generate an additional $20.4 million if fully exercised.
Artelo Biosciences, a clinical-stage pharmaceutical company, has priced a public offering of 441,210 common stock shares and pre-funded warrants, expecting to raise approximately $2.0 million to support its therapeutic development efforts.
Artelo Biosciences is conducting an underwritten public offering of common stock and pre-funded warrants, with R.F. Lafferty & Co., Inc. acting as the sole book-running manager.
The cannabinoid agonist market is gaining momentum with expanding medical cannabis legalization and growing clinical validation for treating chronic pain, epilepsy, and inflammatory conditions. Over 20 pharmaceutical companies are actively developing cannabinoid agonist drugs with promising pipeline candidates.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.